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The effects of 15- and 5-ml doses of magnesium-aluminum hydroxide (MAH) and calcium carbonate (CC)
antacids, respectively, on the bioavailability of ofloxacin after single oral 400-mg doses of ofloxacin were
investigated in a 32-subject, randomized, crossover, open-label study. On four separate occasions, subjects
received ofloxacin alone or antacid 24 h before, 2 h before, or 2 h after ofloxacin administration (n = 16 for
each antacid). CC administration had no significant effect on the rate and extent of ofloxacin absorption
regardless of the timing of antacid administration. A small but significant negative effect ofMAH administra-
tion 2 h before ofloxacin administration was noted as evidenced by area under the curve and peak concentration
in plasma data. Simultaneous administration of ofloxacin with either antacid was not investigated in this study.
It appears that MAH and CC antacids in the doses used in this study generally do not interfere in a clinically
significant manner with the bioavailability of ofloxacin, provided that an interval of at least 2 h separates the
administration of these products.
Ofloxacin is a synthetic carboxyquinolone antimicrobial
agent which exhibits broad-spectrum in vitro bactericidal
activities against gram-positive and gram-negative aerobes
(8). The clinical efficacy of ofloxacin has been documented in
patients with respiratory tract, upper and lower urinary
tract, gonococcal and nongonococcal urethritis, and skin and
soft tissue infections (8, 14).
Coadministration of some antacids and sucralfate has
resulted in diminished absorption of several of the carboxy-
quinolones. This phenomenon has been reported to be due to
the formation of insoluble chelates in the gastrointestinal
tract (5-7, 9-12). Although the majority of these interaction
studies have investigated the quinolone ciprofloxacin, four
reports have suggested the existence of a similar interaction
between antacids and ofloxacin (7, 12; G. Hoffken, P.
Olschewski, B. Sievers, H. Lode, K. Borner, and P.
Koeppe, Program Abstr. 26th Intersci. Conf. Antimicrob.
Agents Chemother., abstr. no. 485, 1986; F. P. V. Maesen,
B. I. Davies, W. H. Geraedts, and C. A. Sumajow, Letter,
J. Antimicrob. Chemother. 19:848-850, 1987).
This study was designed to rigorously characterize the
interaction potential between ofloxacin and two commonly
used antacid preparations: (i) magnesium-aluminum hydrox-
ide (Maalox; Rorer Pharmaceutical Corp., Fort Washington,
Pa.) and (ii) calcium carbonate (Titralac; 3M Riker, St. Paul,
Minn.).
The study was approved by the Human Subjects Research
Committee, Hennepin County Medical Center. Thirty-two
normal, healthy male volunteers who participated in the
study were between the ages of 18 and 40 years, and all
subjects gave written, informed consent prior to participa-
tion. The patients were healthy, as determined by compre-
hensive medical history, physical examination, electrocar-
diography, and laboratory profiles. None of the subjects was
taking medications within 1 week before or during the study.
None of the subjects had a history or current evidence of
* Corresponding author.
significant renal, hepatic, cardiovascular, hematologic, neu-
rologic, psychiatric, respiratory, or metabolic disease.
A parallel study design was followed wherein 16 subjects
were randomly assigned to receive single doses of ofloxacin
(2 x 200 mg, lot 4007; Ortho Pharmaceutical Corporation,
Raritan, N.J.) and calcium carbonate (5 ml) and 16 were to
receive single doses of ofloxacin (2 x 200 mg) and magne-
sium-aluminum hydroxide (15 ml). The assignment of study
phase ordering was achieved by using a Latin square design.
In both study arms, all patients received 400 mg of ofloxacin
alone (regimen 1), ofloxacin preceded 2 h by antacid admin-
istration (regimen 2), ofloxacin followed 2 h later by antacid
administration (regimen 3), and ofloxacin preceded 24 h by
antacid administration (regimen 4). All subjects were fasted
for at least 8 h prior to and for 1 h following administration
of the second component of each regimen. Use of antacids,
bismuth subsalicylate, or other gastrointestinal preparations
at any time during the study period was prohibited. Study
phases were separated by washout periods of at least 4 days.
Blood samples of 5 ml were obtained just prior to ofloxacin
administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h following
ofloxacin administration. Plasma was separated via centrif-
ugation and stored frozen at -20°C until analysis.
The concentration of ofloxacin in plasma was determined
by a high-pressure liquid chromatography method. After
extraction at pH 7 with dichloromethane, the extract was
injected onto a Cl8 ,uBondapak column (25 cm by 4.6 mm[inner diameter]; Waters Associates Inc., Milford, Mass.).
The mobile phase consisted of 1.74 g of potassium dihydro-
gen phosphate and 20 mg of 1-hexanesulfonic sodium salt
(Eastman Kodak Co., Rochester, N.Y.) dissolved in 650 ml
of distilled water, combined with 350 ml of methanol, and
adjusted to pH 3 with phosphoric acid. The imidazolic
derivative of ofloxacin (Daiichi Seiyaku) was used as the
internal standard. Detection was done with a UV detector at
313 nm. The limit of quantitation was 0.01 mg/liter, and the
extraction efficiency was greater than 95%. The assay was
linear over the concentration range of 0.025 to 9 mg/liter.
The intra- and interday coefficients of variation ranged from
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FIG. 1. Mean plasma ofloxacin concentration-versus-time curves
for ofloxacin alone (0), calcium carbonate antacid administered 2 h
prior to ofloxacin (U), calcium carbonate antacid administered 24 h
prior to ofloxacin (0), and calcium carbonate antacid administered 2
h following ofloxacin (O).
3 to 6% over the standard curve concentration range of 0.025
to 9 mg/liter (3).
Peak concentration in plasma (Cmax) and time to achieve
Cmax (Tmax) were determined by visual inspection of the
plasma concentration-versus-time curves. The area under
the plasma concentration-versus-time curve from time zero
to 12 h following administration (AUCO,12) was calculated by
using the linear trapezoidal rule (4). Percent relative bio-
availability was determined as the ratio of the AUC-12 for
the ofloxacin-antacid regimens to the AUCO.12 for the oflox-
acin alone regimen times 100.
Bartlett's test was used to assess the homogeneity of
variance between treatment regimens. Separate analysis of
variance with Tukey's range test was performed for each
antacid to determine between-regimen differences for
AUCO12, Cmax, and T.a values. Power calculations were
performed by the method of Wagner (13) and Cohen (2). All
statistical evaluations were performed by using the Statisti-
cal Analysis System (SAS Institute, Raleigh, N.C.) (1).
Statistical significance was assessed at the 5% level.
Fifteen of 16 and 14 of 16 subjects in the calcium carbonate
and magnesium-aluminum hydroxide treatment groups, re-
spectively, completed the entire study. The dropouts oc-
curred for personal or administrative reasons unrelated to
the study. The mean plasma concentration-versus-time pro-
files for the calcium carbonate and magnesium-aluminum
hydroxide treatment groups are depicted in Fig. 1 and 2,
respectively.
In the calcium carbonate treatment group, there were no
significant differences among regimens 1, 2, 3, and 4 with
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FIG. 2. Mean plasma ofloxacin concentration-versus-time curves
for ofloxacin alone (0), magnesium-aluminum hydroxide antacid
administered 2 h prior to ofloxacin (x), magnesium-aluminum
hydroxide antacid administered 24 h prior to ofloxacin (0), and
magnesium-aluminum hydroxide antacid administered 2 h following
ofloxacin (O).
respect to AUCO.12 or Cmax (Table 1). In addition, no
significant differences among regimens 1, 2, 3, and 4 were
noted with respect to Tmax. The minimum detectable differ-
ences with 80% power for AUCO.12, Cmax, and Tmax were
7.7, 18.0, and 40.0%, respectively.
In the magnesium-aluminum hydroxide treatment groups,
significant differences were seen between regimen 2 (antacid
2 h prior to ofloxacin) and regimens 1, 3, and 4 with respect
to AUCO.12 (16.69 + 3.89, 21.24 + 3.01, 21.61 + 3.48, and
20.23 3.18 mg- h/liter, respectively; P < 0.05) and Cmax
(2.6 1.0, 3.7 + 0.9, 3.8 ± 0.9 and 3.5 ± 0.9 mg/liter,
respectively; P < 0.05) (Table 2). In addition, the Tmax was
significantly longer in regimen 2 than in regimens 3 and 4 (2.0
± 0.7, 1.5 ± 0.5, 1.5 ± 0.5 h, respectively; P < 0.05). The
minimum detectable differences with 80% power for AUC0.
12, Cmax, and Tmax were 12.0, 25.0, and 36.0%, respectively.
The observed mean decreases in AUCO.12 and Cmax and
mean increase in Tmax compared with the control phase were
21.8, 29.7, and 25.0%, respectively.
Indications of a possible interaction between ofloxacin and
aluminum-based antacids have been reported (7, 12; Hoffken
et al., 26th ICAAC; Maesen et al., Letter, J. Antimicrob.
Chemother.). In patients with chronic renal insufficiency,
reductions in ofloxacin efficacy (measured by elimination of
bacterial strains) were associated with concomitant therapy
with aluminum hydroxide phosphate binder therapy (12). In
a study in healthy volunteers, administration of magnesium-
aluminum hydroxide antacid within a 24-h period prior to
ofloxacin administration was reported to reduce oral absorp-
TABLE 1. Pharmacokinetic parametersa for the ofloxacin-calcium carbonate treatment group
(no. of subects) Cmax (mg/liter) Tm, (h) AUCO_12 (mg- h/liter) Relative bioavailability (%)
1 (14) 3.2 ± 0.7 (2.0-4.3) 1.7 ± 0.6 (1.0-3.0) 20.45 ± 3.10 (14.93-26.17) 100
2 (14) 3.3 ± 0.9 (2.0-5.0) 1.4 ± 0.6 (1.0-3.0) 19.68 + 2.60 (13.84-22.82) 103.6 ± 10.8 (75.9-109.5)
3 (16) 3.3 ± 0.7 (2.2-4.6) 1.6 ± 0.8 (1.0-4.0) 20.13 ± 2.42 (15.11-24.40) 97.9 + 9.8c (85.5-111.9)
4 (15) 3.5 ± 0.6 (2.5-4.8) 1.6 ± 0.7 (1.0-3.0) 19.58 ± 2.73 (15.28-24.15) 95.9 ± 8.2c (82.6-111.9)
Values are means
±
standard deviations. Ranges of values are given in parentheses.
b Regimens are described in the text.
c Data are given for 14 subjects.
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TABLE 2. Pharmacokinetic parametersa for the ofloxacin-magnesium-aluminum hydroxide treatment group
Regimenb(no. of subjects) Cm, (mg/liter) Tm. (h) AUCO 12 (mg * h/liter) Relative bioavailability (%)
1 (15) 3.7 ± 0.9 (1.9-5.3) 1.6 ± 0.5 (1.0-3.0) 21.24 ± 3.01 (14.08-25.45) 100
2 (15) 2.6 ± 1.OC (1.3-4.7) 2.0 ± 0.7d (1.0_3.0) 16.69 ± 3.89c (9.47-24.11) 79.2 ± 17.1c (48.4-107.3)
3 (15) 3.8 ± 0.9 (2.0-5.5) 1.5 ± 0.5 (1.0-3.0) 21.61 ± 3.48 (15.04-26.76) 101.9 ± 8.4e (87.2-118.1)
4 (15) 3.5 ± 0.9 (1.9-5.9) 1.5 ± 0.5 (1.0-3.0) 20.23 ± 3.18 (13.77-25.10) 95.3 ± 6.9 (77.7-104.0)
a Values are means ± standard deviations. Ranges of values are given in parentheses.
b Regimens are described in the text.
c P < 0.05 for regimen 2 versus regimens 1, 3, and 4.
d p < 0.05 for regimen 2 versus regimens 3 and 4.
e Data are given for 14 subjects.
tion by as much as 70%. Unfortunately, no details or data are
provided to evaluate this study (Hoffken et al., 26th
ICAAC). In another study in healthy volunteers, concomi-
tant administration of ofloxacin and dry aluminum hydroxide
gel granules with or without water was shown to reduce the
rate and extent of ofloxacin absorption. Unfortunately, the
short blood collection schedule of 6 h following ofloxacin
administration and the lack of detailed data make it difficult
to evaluate the extent of the interaction (7). In a study of
patients with acute exacerbations of chronic bronchitis,
concomitant administration of ofloxacin and magnesium-
aluminum hydroxide antacid was shown to slightly reduce
the extent of ofloxacin absorption by a mean of 21.8%,
although this was not statistically significant (Maesen et al.,
Letter, J. Antimicrob. Chemother.).
The study reported herein demonstrates that there is no
significant interaction between ofloxacin and low doses of
calcium carbonate antacid when administration of the two
agents is separated by at least 2 h. A modest reduction in
ofloxacin absorption may be expected if low-dose magne-
sium-aluminum hydroxide antacid is administered 2 h prior
to ofloxacin.
However, the results of this study should be interpreted
with caution, since the effects of more frequently used
antacid doses of 20 or 30 ml and simultaneous ofloxacin-
antacid administration were not evaluated. Further studies
are required to assess these effects. Until these are studied,
it seems prudent not to administer antacids within 2 h prior
to or following administration of ofloxacin.
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